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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.030The origin of the myoﬁbroblast in ﬁbrotic lung disease is uncertain, and no effective medical therapy for
ﬁbrosis exists. We have previously demonstrated that transforming growth factor-b1 (TGF-b1) induces
pleural mesothelial cell (PMC) transformation into myoﬁbroblasts and haptotactic migration in vitro.
Whether PMC differentiation and migration occurs in vivo, and whether this response can be modulated
for therapeutic beneﬁt, is unknown. Here, using mice recombinant for green ﬂuorescent protein (GFP)
driven by the Wilms tumor-1 (WT-1) promoter, we demonstrate PMC trafﬁcking into the lung and
differentiation into myoﬁbroblasts. Carbon monoxide or the induction of heme oxygenase-1 (HO-1)
inhibited the expression of myoﬁbroblast markers, contractility, and haptotaxis in PMCs treated with
TGF-b1. Intrapleural HO-1 induction inhibited PMC migration after intratracheal ﬁbrogenic injury. PMCs
from patients with idiopathic pulmonary ﬁbrosis (IPF) exhibited increased expression of myoﬁbroblast
markers and enhanced contractility and haptotaxis, compared with normal PMCs. Carbon monoxide
reversed this IPF PMC proﬁbrotic phenotype. WT-1eexpressing cells were present within ﬁbrotic regions
of the lungs in IPF subjects, supporting a role for PMC differentiation and trafﬁcking as contributors to
the myoﬁbroblast population in lung ﬁbrosis. Our ﬁndings also support a potential role for pleural-
based therapies to modulate pleural mesothelial activation and parenchymal ﬁbrosis progression.
(Am J Pathol 2013, 182: 1239e1247; http://dx.doi.org/10.1016/j.ajpath.2012.12.030)Supported in part by National Institute for Occupational Safety and
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pathic interstitial pneumonia, is characterized by cellular and
structural changes in the parenchyma associated with the
proliferation ofmyoﬁbroblasts and deposition of extracellular
matrix components.1 IPF begins in the subpleural region and
extends centrally, resulting in a progressive decline in lung
function. The origin of the pathogenic myoﬁbroblast is un-
certain. The hallmark lesions of IPF, the ﬁbroblastic foci seen
on two-dimensional histopathological slides, were thought
of as discrete sites of epithelial injury and repair.2 Cool et al3
used three-dimensional reconstruction to demonstrate that
these foci are part of a complex, highly interconnected ret-
iculum and suggested the leading edge of the ﬁbroblastic
invasion extends from the pleura to the underlying paren-
chyma like a wave of ﬁbrosis.
The pleura is a metabolically active monolayer of meso-
thelial cells that intimately approximates the lung paren-
chyma. The close proximity of PMCs to the underlying lung
ideally positions them to respond to cytokines, chemokines,stigative Pathology.
.and growth factors released during parenchymal stress,
injury, infection, or inﬂammation. The cytokine transfor-
ming growth factor-b1 (TGF-b1) is a crucial mediator of
epithelialemesenchymal transition (EMT) and acts as a mas-
ter switch for induction of ﬁbrosis in many organs, including
the lung.4e6 PMC transformation into myoﬁbroblasts and
haptotactic migration occur in vitro in response to TGF-b1.7
The concept of pleural mesothelialemesenchymal transition
(MMT) was investigated in a recent study demonstrating
PMCmigration into the lung and expression of myoﬁbroblast
phenotypic markers. This study demonstrated the presence
Zolak et alof PMCs in the lung parenchyma of patients with IPF and
a correlation with disease severity and the degree of ﬁbrosis.8
PMC differentiation into myoﬁbroblasts and subsequent
migrationmayplay a crucial role in the development ofﬁbrotic
lung disease.
Heme oxygenase-1 (HO-1) is the inducible form of the rate-
limiting enzyme involved in the degradation of heme with
the generation of equimolar quantities of carbon monoxide
(CO), iron, and biliverdin.9 HO-1 induction with subsequent
CO production is highly sensitive to numerous stimuli and
cellular insults that cause oxidative stress.10 Such induction
represents a beneﬁcial response to injurious stimuli in dive-
rse diseases, including atherosclerosis, sepsis, and ﬁbrosis. The
protectiveeffects ofHO-1andCOaredue toanti-inﬂammatory,
antiapoptotic, antioxidant, and antiproliferative properties.11
Indeed, HO-1 deﬁciency has been associated with increased
ﬁbrosis, tubular TGF-b1 expression, inﬂammation, and enh-
anced EMT in a model of obstructive kidney disease.12 Up-
regulation of HO-1 provides protection against renal injury
after unilateral ureteral obstruction and suppression of tubu-
lointerstitial ﬁbrosis via anti-apoptotic pathway modulation.13
Additionally, adenoviral transfer of the HO-1 gene, as well
as administration of CO and bilirubin, has been associated
with suppression of ﬁbrosis in animal models of ﬁbrotic
lung disease.14,15 Here, we present deﬁnitive evidence for
the presence of PMCs in the lung parenchyma of patients
with IPF and show that the ﬁbrotic disposition of these cells
can be reversed by CO and HO-1 pathway modulation in
vitro. Furthermore, using animal models of lung injury, we
demonstrate PMC differentiation into myoﬁbroblasts and
parenchymal invasion that is inhibited by intrapleural HO-1
induction.
Materials and Methods
Cell Culture
Mouse wild-type PMCs of passages between 15 and 35 were
used. Cells were grown in F12K medium (catalog no. 11765-
054; Life TechnologieseInvitrogen, Carlsbad, CA) supple-
mented with heat-inactivated fetal bovine serum (10%) or in
serum-free conditions before (16 hours) and during TGF-b1
treatments. Human PMCs were derived from lung explants
from patients diagnosed with IPF undergoing lung trans-
plantation. Cells were cultured in Medium 199 (catalog no.
11150-059; Life TechnologieseInvitrogen) supplemented
with epidermal growth factor (EGF) and 10% fetal bovine
serum or in serum-free conditions without EGF before and
during TGF-b1 exposure.
Cytokine Treatments
Cells were serum-starved for 16 hours and then were treated
with 5 ng/mL TGF-b1 (catalog no. 101-B1; R&D Systems,
Minneapolis, MN) activated in 4 mmol/L HCl, 0.5% bovine
serum albumin.1240Induction of HO-1
Cells were treated with 5 mmol/L hemin in dimethyl sulfoxide
(catalogno. 51280-1G;Sigma-Aldrich,St.Louis,MO) ineither
serum-free conditions or in 10% fetal bovine serum medium,
depending on the experimental design. Cells were treated with
2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-
Im) at doses of 25 nmol/L or 50 nmol/L, depending on the
experiment. The CDDO-Im was provided by Michael Sporn
and Karen Liby of Dartmouth Medical School.
CO Treatment
Tricarbonyldichlororuthenium (II) (CORM-2)was purchased
from Sigma-Aldrich (catalog no. 288144-500 MG). Cells
were exposed to CORM-2 dissolved in dimethyl sulfoxide
(10 mmol/L), which served as a source of CO.
Collagen Gel Contraction
Transformed normal pleural mesothelial cells (Met5A)
or PMCs from patients with IPF were seeded at a density of
1  106 cells/mL. Cells and serum medium were mixed with
rat tail collagen reconstituted in 0.1 mol/L acetic acid (catalog
no. C7661-50 MG; Sigma-Aldrich) in a 3:1 proportion and
seeded in individual wells in a 24-well culture dish. Cells
were allowed to acclimatize for 16 hours and then were
pretreated with hemin, CDDO-Im, or CORM-2 for 30 min-
utes, followed by addition of 5 ng/mL TGF-b1; cells were
allowed to contract for 48 hours.
Western Blotting
All protein isolates were prepared with radioimmunopreci-
pitation assay buffer. Sampleswere sonicated at 4C, followed
by centrifugation to remove insoluble material, and then were
subjected to protein assay using a Micro BCA kit (Pierce;
Thermo Fisher Scientiﬁc, Rockford, IL). All protein levels
were adjusted to identical concentrations, followed by
reducing with 0.1 mol/L dithiothreitol and resolved on
4 to 20% NuPAGE minigels (catalog no. NP0320; Life
TechnologieseInvitrogen) using a morpholine propane
sulfonic acid (NP0001) buffer system; samples were then
transferred to nitrocellulose membrane (catalog no. 162-0115;
Bio-RadLaboratories,Hercules, CA), followed by blocking in
5% nonfat dry milk reconstituted in Tris-buffered saline/
Tween (pH 7.4) (TBST). The following antibodies were used
for immunoblotting: a-SMA mouse monoclonal (1:1000;
catalog no. 03-61001; American Research Products, Belmont,
MA), b-actin mouse monoclonal (1:2000; catalog no. A5441;
Sigma-Aldrich), HO-1 rabbit polyclonal (1:1000; catalog no.
ADI-SPA-895; Enzo Life Sciences International, Plymouth
Meeting, PA), horseradish peroxidase conjugated a-rabbit
IGG (1:5000; catalog no. 31462; Thermo Fisher Scientiﬁc),
a-mouse IGM (1:5000; catalog no. 31432; Thermo Fi-
sher Scientiﬁc), and NOX-4 (catalog no. NB110-58849;ajp.amjpathol.org - The American Journal of Pathology
Figure 1 PMCs are present in the explanted lungs from patients with IPF.
Sixteen explanted lungs from 16 patients with IPF were preserved after lung
transplantation and specimens were stained (brown) for WT-1 on standard
microscope slides. Immunohistochemistry revealed abnormal presence ofWT-
1þ cells within the parenchyma of an explanted lung (representative of 16
explanted lungs). The boxed area in the top panel is presented at higher
magniﬁcation in the bottom panel. Scale bars: 100 mm (top panel); 40 mm
(bottom panel).
Figure 2 HO-1 induction or treatment with the CO-releasing molecule
CORM-2 inhibits PMC differentiation into myoﬁbroblasts. A: Wild-type mouse
PMCs were treated with CDDO-Im (50 nmol/L) after treatment with TGF-b1
(5 ng/mL). B: Wild-type mouse PMCs were left untreated (control) or were
treated with TGF-b1 alone for 48 hours, or with both TGF-b1 and either hemin
(5 mmol/L) or CORM-2 (10 mmol/L) for 48 hours. Representative Western
blots demonstrate expression of a-SMA, NOX-4, HO-1, and b-actin.
PMCs in Lung FibrosisNovus Biologicals). All primary antibodies were prepared in
5%nonfat drymilk reconstituted inTBST (pH7.4) and probed
overnight at 4C, followed by three washes and then incu-
bation with appropriate horseradish peroxidase conjugated
secondary antibody at room temperature for 2 hours. The
immunoblots were then washed ﬁve times in TBST, followed
by developing with chemiluminescent substrate application
(Pierce ECL, catalog no. 32106; Thermo Fisher Scientiﬁc).
Mouse Models
To investigate the effects of HO-1 during bleomycin injury,
we used a pleural delivery model in wild-type and Hmox/
mice on a C57BL/6J background. To track PMCs, we used
a transgenic mouse model that constitutively expresses GFP
in Wt1-expressing cells (Wt1tm1(EGFP/cre)Wtp/J).
Cell Migration Assays
Haptotaxis assays were performed in Costar Transwell mi-
gration chambers (Corning Life Sciences, Corning, NY)
as described previously, with modiﬁcations.7 In brief, the
lower sides of the ﬁlters were coated with 1 mg/mL bovine
serum albumin, or TGF-b1, or were left untreated and keptThe American Journal of Pathology - ajp.amjpathol.orgovernight at 37C in humidiﬁed air in the presence of 5%CO2.
The ﬁlters were removed, washed with PBS, and air-dried.
Filters were placed into 48-well plates. The lower portion of
the chamber was ﬁlled with Medium 199 (Life Tech-
nologieseInvitrogen) with 1% fetal bovine serum. PMCs (1
105 cells) treated with TGF-b1 alone, with TGF-b1 and either
CDDO-Im, CORM-2, or hemin, or with no treatment (control)
were seeded into the upper chamber and incubated for 6 hours
at 37C. At the end of incubation, medium from the upper well
was discarded. The upper sides of the ﬁlters were scraped to
remove adherent cells. Theﬁlterswere removed, and cellswere
ﬁxed in formalin and stained with 20% Giemsa stain (catalog
no. 48900, Fluka; Sigma-Aldrich). The number of cells that
migratedwas quantiﬁed by counting the number of cells on the
distal surface of the ﬁlter under an optical microscope. The
results are expressed as the haptotactic index [ie, the number of
cells visualized per 20 high-power (40) ﬁelds]. Coating the
ﬁlters with TGF-b1 acts as an attractant for the PMCs.
Explanted Lungs
Sixteen lungs from16 patientswith IPF, eight lungs from eight
patients with COPD, two lungs from two patients with cystic
ﬁbrosis, and one lung from one patientwith pulmonary arterial
hypertension, were preserved after lung transplantation at the
University of Alabama at Birmingham (Birmingham, AL),1241
Zolak et alwith informed consent. PMCs from explanted lungs were ob-
tained by surface scraping of the visceral pleura and used in
passages 2 to 4. PMCs expressed calretinin, mesothelin, and
WT-1. Lung specimens were ﬁxed in formalin, embedded in
parafﬁn, and sectioned with a microtome before immunohisto-
chemical staining on standard microscope slides.
Imaging
For ﬂuorescence imaging, an Olympus BX51 microscope
was used (40 lens, numerical aperture of 1.3; Olympus
America, Center Valley, PA). The ﬂuorochromes used were as
follows: for green ﬂuorescent protein (GFP), Alexa Fluor 488
anti-chicken; for smooth muscle actin, Alexa Fluor 594 anti-
mouse (Life TechnologieseInvitrogen). DAPI was used as
a nuclear counterstain. A Retiga camera was used (12-bit color;
QImaging, Surrey, BC, Canada) with light microscopy and
Bioquant Osteo 2009 (Bioquant Image Analysis, Nashville,
TN). For immunohistochemistry, an Axiovert 200M light
microscope was used (40 lens, numerical aperture 1.3; Carl
Zeiss, Göttingen, Germany), at room temperature, with glass
slides and bright-ﬁeld ﬂuorochromes. Images were captured
using a QImaging QIClick camera andQCapture Pro version 7
software (QImaging, Surrey, BC, Canada).
All human and animal studies were approved by the
Institutional Review Board at the University of Alabama at
Birmingham. Written informed consent was obtained from
the participants before inclusion in the study.
Results
PMCs Are Present in Lung Explants from Patients with
IPF
WT-1 is a zinc-ﬁnger protein that regulates many pro-
perties of the developing mesothelium. It is expressed inFigure 3 HO-1 modulates PMC contractility. Normal PMCs (A) and PMCs from
TGF-b1 (5 ng/mL) alone or were pretreated with hemin (5 mmol/L), CDDO-Im (25 n
allowed to contract for 48 hours. Gel area was subsequently measured as a surrogat
control and cotreated samples (A) or versus control (B); **P < 0.05 versus TGF-
1242mesoderm-derived tissue, including normal pleural meso-
thelium, but is absent in normal lung, making it an ideal
marker of PMCs. WT-1eexpressing PMCs have been shown
to migrate into the lung parenchyma to form smooth muscle
cells of the vascular wall and other cells of the lung
mesenchyme during mouse lung development.16 The major
role of WT-1 in mesenchymal differentiation and deve-
lopment has implications for lung pathology, including
pulmonary ﬁbrosis. In the present study, using immunohis-
tochemistry, we have demonstrated the abnormal presence
of WT-1þ cells within the parenchyma of an explanted
lung from a representative patient with IPF, one of the 16
explanted lungs that underwent immunohistochemistry for
WT-1 (Figure 1). WT-1þ cells were absent from the
explanted lungs of patients with non-IPF interstitial lung
disease, cystic ﬁbrosis, and chronic obstructive pulmonary
disease (data not shown).HO-1 Induction or Treatment with a CO-Releasing
Molecule Inhibits PMC Differentiation into
Myoﬁbroblasts in Response to TGF-b1 in Mouse PMCs
Treatment of mouse PMCs with TGF-b1 increased expres-
sion of the myoﬁbroblast marker a-smooth muscle actin
(a-SMA) and NADPH oxidase-4 (NOX-4). NOX-4 has been
shown to mediate myoﬁbroblast activation and ﬁbrogenic
responses to lung injury. NOX-4edependent generation of
hydrogen peroxide is required for TGF-b1einduced myoﬁ-
broblast differentiation, extracellular matrix production, and
contractility.17 CDDO-Im, a synthetic triterpenoid, is a multi-
functional molecule with antiproliferative, antidifferentiating,
and anti-inﬂammatory activities that at nanomolar concen-
trations induces the expression of HO-1.18 To investigate the
effects ofHO-1 induction on PMCdifferentiation andﬁbrosis,
we treated mouse PMCs with TGF-b1 with and withoutpatients with IPF (B) were seeded on collagen wells and were treated with
mol/L), or CORM-2 (10 mmol/L) for 30 minutes before TGF-b1; the PMCs were
e for PMC contractility. Data are expressed as means  SD. *P < 0.05 versus
b1 alone and CDDO-Im þ TGF-b1 (B).
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 HO-1 induction and the CO-releasing molecule CORM-2
modulate PMC migration. Haptotaxis assays in normal PMCs (A) and in
PMCs from patients with IPF (B) were performed in Transwell migration
chambers. PMCs (1  105 cells) treated with TGF-b1 alone (5 ng/mL),
with the same TGF-b1 and either CDDO-Im (25 nmol/L), CORM-2
(10 mmol/L), or hemin (5 mmol/L , or with no treatment (control) were
seeded into the upper chamber and incubated for 6 hours at 37C. The
haptotactic index was determined as the number of migrated cells visu-
alized per 20 high-power ﬁelds (HPF). Data are expressed as means  SD.
**P < 0.05.
PMCs in Lung Fibrosisadministration of CDDO-Im. CDDO-Im administration at
the time of PMC treatment with TGF-b1 caused an increase
in HO-1 expression and a decrease in NOX-4 and a-SMA
expression. Treatment with ferriprotoporphyrin IX chloride
(hemin), a physiological HO-1 inducer, increased HO-1 and
decreased expression of NOX-4 and a-SMA in PMCs treated
with TGF-b1. Treatment with CORM-2, a CO-releasing
molecule, similarly inhibited NOX-4 and a-SMA expr-
ession (Figure 2). Taken together, these results demonstrate
a role for HO-1 in the prevention of PMC MMT into
myoﬁbroblast-like cells.
HO-1 Induction and CO Inhibit PMC Contractility
We performed functional gel contraction assays to investi-
gate the effects of HO-1 induction and CO on the response
to TGF-b1 of PMCs from both healthy subjects and patients
with IPF. PMCs were treated with TGF-b1 alone or were
treated with either hemin, CDDO-Im, or CORM-2 before
TGF-b1. In normal human PMCs, gel contraction was
signiﬁcantly decreased in control and in all three cotreat-
ments, compared with TGF-b1 alone (Figure 3A). The
PMCs from patients with IPF exhibited inherent contrac-
tility, even without TGF-b1 treatment, with no signiﬁcant
difference in gel area (a surrogate for PMC contractility)
between control PMCs and TGF-b1etreated PMCs from
patients with IPF. Cotreatment with hemin and TGF-b1, but
not with CDDO-Im and TGF-b1, caused a signiﬁcant
increase in gel area; the addition of CORM-2 to TGF-
b1etreated IPF PMCs likewise caused a signiﬁcant increase
in gel area. These ﬁndings suggest reversion to a more
normal PMC phenotype (Figure 3B). The data demonstrate
a role for HO-1 induction or CO in preventing the
contractile phenotype of normal PMCs treated with TGF-b1
and for reversing contractility in PMCs from patients with
IPF.
HO-1 Induction and CO Prevent PMC Haptotaxis in
Normal PMCs and PMCs from Patients with IPF
Haptotaxis assays were performed in Transwell migration
chambers. Haptotaxis (ie, cell movement in response to
gradients immobilized on a substratum) is distinct from che-
motaxis, which is deﬁned as cell migration along a concen-
tration gradient of solubilized molecules. Haptotaxis more
closely represents cell movement in the extracellular matrix.
Normal PMCs (1  105 cells) were treated with TGF-b1
alone, or with CDDO-Im, CORM-2, or hemin treatment fol-
lowed by TGF-b1; untreated cells were used as control. The
number of migrated cells was quantiﬁed, and data were
expressed as the haptotactic index. Treatment with TGF-b1
caused signiﬁcant haptotaxis, whichwas inhibited byCDDO-
Im, CORM-2, and hemin (Figure 4A). Haptotaxis assays with
IPF PMCs, performed as described above, demonstrated
increased baseline haptotaxis, along with increased hapto-
taxis after treatment with TGF-b1 that was signiﬁcantlyThe American Journal of Pathology - ajp.amjpathol.orginhibited by hemin or CORM-2 cotreatment, but not by
CDDO-Im (Figure 4B).
HO-1 Deﬁciency Potentiates Pleural and Subpleural
Fibrosis in Mice
To further investigate the role of HO-1 in vivo in pleural and
parenchymal ﬁbrosis, we administered intrapleural bleo-
mycin to Hmox/ and Hmoxþ/þ mice. Trichrome staining
for collagen and H&E staining demonstrated a more robust
pleural ﬁbrotic response in HO-1edeﬁcient mice, compared
with wild-type mice (Figure 5).
Mouse PMCs Undergo MMT and Migrate into the Lung
Parenchyma after Intratracheal TGF-b1
To track PMC migration, we used heterozygotic mice
recombinant for GFP driven by the WT-1 promoter. At 24
hours after intratracheal TGF-b1 treatment, we observed
GFPþ cells inside the lung parenchyma (Figure 6A). The1243
Figure 5 HO-1 deﬁciency predisposes mice to
pleural and subpleural ﬁbrosis. Intrapleural bleo-
mycin (4 U/kg) was administered to Hmoxþ/þ and
Hmox/ mice; the ﬁbrotic response was evaluated
at 21 days. A and B: H&E staining (A), with pleural
thickness (B) measured in the same mice. C and D:
Trichrome staining for collagen (C), with pleural
thickness (D) measured in the same mice. Images
are representative of six Hmoxþ/þ and six Hmox/
mice. Scale bars: 152 mm (A and C, left panels);
303 mm (A and C, right panels).
Zolak et alGFPþ cells costain for a-SMA, further supporting the
concept that PMCs have not only migrated into the lung
in response to inhaled stimuli, but have also underg-
one differentiation to express a myoﬁbroblast phenotype
(Figure 6B).Intrapleural HO-1 Induction with CDDO-Im Prevents
PMC Migration after Inhaled Fibrogenic Stimulus in
Mice
To test the effects of pleural HO-1 induction on paren-
chymal PMC migration and ﬁbrosis, we treated six wild-
type mice with either intratracheal bleomycin alone or
intratracheal bleomycin combined with intrapleural CDDO-
Im. Control mice treated with intratracheal bleomycin
alone exhibited WT-1þ cells along the pleura and in
the parenchyma at 21 days after bleomycin treatment.
Mice treated with intrapleural CDDO-Im at day 3 after1244bleomycin treatment exhibited WT-1 staining exclusively
along the pleura at 21 days after bleomycin treatment
(Figure 7). Intrapleural HO-1 induction thus prevented
parenchymal PMC migration in response to an inhaled
ﬁbrotic stimulus.Hemin, CORM-2, and CDDO-Im Inhibit Myoﬁbroblast
Marker Expression in PMCs from Patients with IPF
We measured expression of a-SMA, NOX-4, and HO-1 in
PMCs from patients with IPF, both before and after treat-
ment with TGF-b1, with or without hemin, CORM-2, or
CDDO-Im treatment. PMCs from IPF patients exhibited
a predisposition to robustly express NOX-4 and a-SMA at
baseline and also after TGF-b1. Treatment with hemin,
CORM-2, or CDDO-Im decreased expression of myoﬁ-
broblast markers (Figure 8). Interestingly, the induction of
HO-1 in IPF PMCs appeared less robust than in similarFigure 6 Mouse PMCs undergo MMT transition
and parenchymal invasion in response to intra-
tracheal TGF-b1. A: Heterozygotic mice recombi-
nant for GFP driven by the WT-1 promoter were
treated with intratracheal PBS as control or
intratracheal TGF-b1 to track PMCs. Immunoﬂuo-
rescence staining was performed for GFP (green)
at 24 hours after intratracheal TGF-b1 treatment.
DAPI was used as a nuclear counterstain (blue). B:
Merged images demonstrate colocalization of GFP
and the myoﬁbroblast marker a-SMA (red). A white
dotted line approximates the location of the pleura.
Scale barZ 100 mm.
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Figure 7 PMC parenchymal migration is in-
hibited by intrapleural HO-1 induction. Wild-type
mice were treated with intratracheal bleomycin
(50 mU/mL) alone (A) or intratracheal bleomycin
followed by intrapleural CDDO-Im (25 nmol/L) at
day 3 after bleomycin treatment (B), to test the
effects of pleural HO-1 induction on PMC migra-
tion. Mice were sacriﬁced at 21 days after bleo-
mycin treatment, and immunohistochemistry was
performed for WT-1. PMCs expressing WT-1 are
marked with arrows. Images are representative of
six mice. Scale bar Z 40 mm.
PMCs in Lung Fibrosisexperiments performed in normal human PMCs (data not
shown).
Discussion
The subpleural distribution of ﬁbrosis in IPF is unexplained.
Morphometric analysis of histological sections of usual
interstitial pneumonia from patients with IPF using three-
dimensional reconstruction shows the ﬁbroblastic foci of
usual interstitial pneumonia at the leading edge of a retic-
ulum that extends from the pleura to the underlying paren-
chyma.3 In another study, carbon particles administered to
the chest cavity of mice along with intratracheal bleomycin
resulted in severe pleural ﬁbrosis.19 This was associated with
progressive subpleural ﬁbrosis, similar to IPF. The authors
concluded that the PMCs had acquired myoﬁbroblast cha-
racteristics and that the matrix accumulation within the sub-
pleural area had evolved through mesothelialeﬁbroblastoid
transformation.
The origin of the myoﬁbroblast in IPF is uncertain. These
pathogenic cells have been variously proposed to be derived
from local mesenchymal cells, circulating ﬁbroblasts, and
epithelial cells that have undergone EMT.20 In experimental
models of pulmonary ﬁbrosis, both EMT and bone marrowFigure 8 The ﬁbrotic disposition of PMCs from patients with IPF can be over
a-SMA, NOX-4, and HO-1 in PMCs from patients with IPF in response to treatment
hemin (5 mmol/L), (B) the CO-releasing molecule CORM-2 (10 mmol/L), or (C) CD
The American Journal of Pathology - ajp.amjpathol.orgprogenitors contribute to the ﬁbroblast population. How-
ever, neither is a principal contributor to lung myoﬁbro-
blasts.21 The role of EMT and MMT in development and
disease pathogenesis is established in other organs. HO-1
deﬁciency is associated with increased ﬁbrosis, tubular
TGF-b1 expression, inﬂammation, and enhanced EMT in
obstructive kidney disease.12 Recently, our research group
reported PMC transformation into myoﬁbroblasts and hap-
totactic migration in response to TGF-b1 in vitro.7 Subse-
quently, our research group reported that PMCs migrate into
the lung and display myoﬁbroblast phenotypic markers;
importantly, their presence correlated with the severity of
ﬁbrosis in IPF.8
Serosal surfaces play an integral role in organogenesis and
development. The mesothelial covering of the embryonic
heart is a major source of cells to the coronary system.22e25
Wilm et al26 used WT-1eCre genetic lineage marking to
demonstrate that serosal mesothelial cells differentiate into
smooth muscle of all major blood vessels in the mesenteries
and gut. The ability of PMCs to undergo transformation and
migration plays a crucial role in the developing lung. A recent
study of mouse lung development demonstrated that the
mesothelial cells covering the lung surface contribute to
a variety of cell types in the lung, including vascular smoothcome with treatment. Western blotting was used to assess in expression of
with TGF-b1 (5 ng/mL) with and without pretreatment for 48 hours with (A)
DO-Im (25 nmol/L).
1245
Zolak et almuscle cells and possibly also alveolar myoﬁbroblasts and
interstitial ﬁbroblasts.16 The authors suggested a common
mechanism linking the development of coelomic organs
with the maturation of the internal vasculature and postulated
that adult PMCs are multipotent and possibly able to give
rise to mesenchymal cells during injury, repair, or patho-
logy. A subsequent study provided deﬁnitive evidence of
the multipotent capacity of PMCs by demonstrating differ-
entiation into osteoblast and adipocyte-like cells when
exposed to an appropriate growth medium; the authors
concluded that mesothelial cell differentiation is a potential
source of the different tissue types found in malignant
mesothelioma and other serosal pathologies, suggesting
potential roles in regenerative therapies.27 Is it noteworthy that
WT-1eexpressing cells have a capacity to switch between
mesenchymal and epithelial states.28 This may indicate
that WT-1 expression is necessary, but not sufﬁcient, to per-
mit the transition between mesothelial and mesenchymal
phenotypes.
The pleura is a metabolically active monolayer of meso-
thelial cells that intimately approximates the lung paren-
chyma. This proximity of PMCs to the underlying lung
ideally positions them to respond to signals released during
parenchymal stress, whether mechanical, inﬂammatory, or
infectious. In fact, a recent magnetic resonance imaging study
in rats demonstrated the appearance of a marked inﬂamma-
tory signal arising from the pleura 6 hours after inhaled
antigen or endotoxin; the inﬂammatory signal correlated with
a histological analysis revealing severe pleural cavity
edema.29 The reciprocal communication that occurs between
the pleura and parenchyma in the developing lung may
therefore continue in the adult and contribute to disease.
With the present study, we have demonstrated in vitro
PMC differentiation and acquisition of a myoﬁbroblast phe-
notype, as evidenced by expression of mesenchymal markers
and functional assays, including haptotaxis and gel con-
traction, in response to TGF-b1 treatment. Furthermore,
induction of HO-1 or treatment with CO abrogated PMC
differentiation and/or MMT and parenchymal migration.
HO-1edeﬁcient mice also experienced greater pleural ﬁb-
rosis in response to intrapleural bleomycin treatment, com-
pared with wild-type mice.
WT-1þ cells were present in lung explants from patients
with IPF, but not in explants from patients with cystic ﬁbrosis
or chronic obstructive pulmonary disease (data not shown).
Importantly, the present study is the ﬁrst to demonstrate
signiﬁcant phenotypic and functional differences in PMCs
from patients with IPF, compared with normal PMCs.
Strikingly, IPF PMCs displayed a propensity to express the
myoﬁbroblast-speciﬁc marker a-SMA, as well as NOX-4,
a known driver of myoﬁbroblast activation and ﬁbrotic
responses to lung injury.17 Not only did IPF PMCs express
myoﬁbroblast markers, but they also exhibited increased
contractility and propensity for migration. Inducibility of
HO-1 expression in PMCs from patients with IPF was lower,
compared with normal PMCs, suggesting an inherent or1246acquired defect. Abnormalities or deﬁciencies in HO-1
expression or activity in IPF may predispose these patients
to ﬁbroblast proliferation and progressive disease.
There is a potential to use HO-1 modulation and CO as
therapies for ﬁbrotic lung disease. Studies in other organ
systems have shown, using mouse models, that HO-1 ind-
uction opposes pathological postinfarction left ventricular
remodeling30 and prevents the progression of liver ﬁbrosis.31
CO also suppresses bleomycin-induced lung ﬁbrosis in
mice.32 Pioneering work by Ryter and Choi33 has opened the
exciting prospect of translational applications for HO-1
research. In fact, a phase 2 study is recruiting participants
(Study of Inhaled Carbon Monoxide to Treat Idiopathic
Pulmonary Fibrosis; http://www.clinicaltrials.gov/ct2/show/
NCT01214187, last accessed February 9, 2013).
In the present study, treatment of PMCs with CO in the
form of CORM-2 or hemin not only prevented or reversed
the expression of a-SMA and NOX-4, but also signiﬁcantly
attenuated the contractile phenotype of IPF PMCs and PMC
haptotaxis. It is important to note that, although hemin and
CORM-2 reversed the increased gel contraction and hapto-
taxis seen in TGF-b1etreated PMCs, CDDO-Im was unable
to rescue the TGF-b1etreated IPF PMCs. This suggests that
HO-1 induction alone may be insufﬁcient to protect against
ﬁbrosis in IPF. Perhaps an inherent or acquired HO-1 sub-
strate deﬁciency also predisposes to IPF disease. The down-
stream products of the heme oxygenase reaction may hold
more promise for modulating PMC ﬁbrotic phenotypic
expression. The present ﬁndings raise the possibility that
intrapleural modulation of HO-1 or delivery of CO to the
pleural space could contribute to novel strategies in the trea-
tment of IPF by inhibiting PMC differentiation and paren-
chymal trafﬁcking.
Acknowledgments
The authors thank Drs. Michael Sporn and Karen Liby for
providing the CDDO-Im.
References
1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence
and prevalence of idiopathic pulmonary ﬁbrosis. Am J Respir Crit Care
Med 2006, 174:810e816
2. Gross TJ, Hunninghake GW: Idiopathic pulmonary ﬁbrosis. N Engl J
Med 2001, 345:517e525
3. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK:
Fibroblast foci are not discrete sites of lung injury or repair: the
ﬁbroblast reticulum. Am J Respir Crit Care Med 2006, 174:654e658
4. Hills CE, Squires PE: TGF-beta1-induced epithelial-to-mesenchymal
transition and therapeutic intervention in diabetic nephropathy. Am J
Nephrol 2010, 31:68e74
5. Meindl-Beinker NM, Dooley S: Transforming growth factor-beta and
hepatocyte transdifferentiation in liver ﬁbrogenesis. J Gastroenterol
Hepatol 2008, 23(Suppl 1):S122eS127
6. Yáñez-Mó M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M,
Domínguez-Jiménez C, Jiménez-Heffernan JA, Aguilera A, Sánchez-
Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A,ajp.amjpathol.org - The American Journal of Pathology
PMCs in Lung FibrosisGamallo C, Sánchez-Madrid F, López-Cabrera M: Peritoneal dialysis
and epithelial-to-mesenchymal transition of mesothelial cells [Erratum
appeared in N Engl J Med 2005, 353:2827]. N Engl J Med 2003, 348:
403e413
7. Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA,
Fernandez-Bussy S, Antony VB: Pleural mesothelial cell trans-
formation into myoﬁbroblasts and haptotactic migration in response to
TGF-beta1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009, 297:
L115eL124
8. Mubarak KK, Montes-Worboys A, Regev D, Nasreen N,
Mohammed KA, Faruqi I, Hensel E, Baz MA, Akindipe OA,
Fernandez-Bussy S, Nathan S, Antony V: Parenchymal trafﬁcking of
pleural mesothelial cells in idiopathic pulmonary ﬁbrosis. Eur Respir J
2012, 39:133e140
9. Tenhunen R, Marver HS, Schmid R: The enzymatic conversion of
heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci
USA 1968, 61:748e755
10. Keyse SM, Tyrrell RM: Heme oxygenase is the major 32-kDa stress
protein induced in human skin ﬁbroblasts by UVA radiation, hydrogen
peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989, 86:
99e103
11. Jarmi T, Agarwal A: Heme oxygenase and renal disease. Curr
Hypertens Rep 2009, 11:56e62
12. Kie JH, Kapturczak MH, Traylor A, Agarwal A, Hill-Kapturczak N:
Heme oxygenase-1 deﬁciency promotes epithelial-mesenchymal tran-
sition and renal ﬁbrosis. J Am Soc Nephrol 2008, 19:1681e1691
13. Kim JH, Yang JI, Jung MH, Hwa JS, Kang KR, Park DJ, Roh GS,
Cho GJ, Choi WS, Chang SH: Heme oxygenase-1 protects rat kidney
from ureteral obstruction via an antiapoptotic pathway. J Am Soc
Nephrol 2006, 17:1373e1381
14. Tsuburai T, Suzuki M, Nagashima Y, Suzuki S, Inoue S, Hasiba T,
Ueda A, Ikehara K, Matsuse T, Ishigatsubo Y: Adenovirus-mediated
transfer and overexpression of heme oxygenase 1 cDNA in lung
prevents bleomycin-induced pulmonary ﬁbrosis via a Fas-Fas ligand-
independent pathway. Hum Gene Ther 2002, 13:1945e1960
15. Wang HD, Yamaya M, Okinaga S, Jia YX, Kamanaka M,
Takahashi H, Guo LY, Ohrui T, Sasaki H: Bilirubin ameliorates
bleomycin-induced pulmonary ﬁbrosis in rats. Am J Respir Crit Care
Med 2002, 165:406e411
16. Que J, Wilm B, Hasegawa H, Wang F, Bader D, Hogan BL: Meso-
thelium contributes to vascular smooth muscle and mesenchyme
during lung development. Proc Natl Acad Sci USA 2008, 105:
16626e16630
17. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC,
Pennathur S, Martinez FJ, Thannickal VJ: NADPH oxidase-4 mediates
myoﬁbroblast activation and ﬁbrogenic responses to lung injury. Nat
Med 2009, 15:1077e1081
18. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R,
Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-
Kapturczak N, Agarwal A, Sporn MB: The synthetic triterpenoids,
CDDO and CDDO-imidazolide, are potent inducers of heme
oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005, 65:
4789e4798The American Journal of Pathology - ajp.amjpathol.org19. Decologne N, Wettstein G, Kolb M, Margetts P, Garrido C, Camus P,
Bonniaud P: Bleomycin induces pleural and subpleural ﬁbrosis in the
presence of carbon particles. Eur Respir J 2010, 35:176e185
20. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary ﬁbrosis. Lancet
2011, 378:1949e1961
21. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W,
Sherrill TP, Plieth D, Neilson EG, Blackwell TS, Lawson WE:
Contribution of epithelial-derived ﬁbroblasts to bleomycin-induced
lung ﬁbrosis. Am J Respir Crit Care Med 2009, 180:657e665
22. Dettman RW, Denetclaw W Jr, Ordahl CP, Bristow J: Common epicar-
dial origin of coronary vascular smooth muscle, perivascular ﬁbroblasts,
and intermyocardial ﬁbroblasts in the avian heart. Dev Biol 1998, 193:
169e181
23. Männer J: Does the subepicardial mesenchyme contribute myocardio-
blasts to the myocardium of the chick embryo heart? A quail-chick
chimera study tracing the fate of the epicardial primordium. Anat Rec
1999, 255:212e226
24. Mikawa T, Borisov A, Brown AM, Fischman DA: Clonal analysis of
cardiac morphogenesis in the chicken embryo using a replication-
defective retrovirus: I. Formation of the ventricular myocardium.
Dev Dyn 1992, 193:11e23
25. Reese DE, Mikawa T, Bader DM: Development of the coronary vessel
system. Circ Res 2002, 91:761e768
26. Wilm B, Ipenberg A, Hastie ND, Burch JB, Bader DM: The serosal
mesothelium is a major source of smooth muscle cells of the gut
vasculature. Development 2005, 132:5317e5328
27. Lansley SM, Searles RG, Hoi A, Thomas C, Moneta H, Herrick SE,
Thompson PJ, Newman M, Sterrett GF, Prêle CM, Mutsaers SE:
Mesothelial cell differentiation into osteoblast- and adipocyte-like
cells. J Cell Mol Med 2011, 15:2095e2105
28. Scholz H, Kirschner KM: Oxygen-dependent gene expression in
development and cancer: lessons learned from the Wilms’ tumor gene,
WT1. Front Mol Neurosci 2011, 4:4
29. Quintana HK, Cannet C, Schaeublin E, Zurbruegg S, Sugar R,
Mazzoni L, Page CP, Fozard JR, Beckmann N: Identiﬁcation with
MRI of the pleura as a major site of the acute inﬂammatory effects
induced by ovalbumin and endotoxin challenge in the airways of the
rat. Am J Physiol Lung Cell Mol Physiol 2006, 291:L651eL657
30. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X,
Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG,
Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD: Car-
dioprotective and antiapoptotic effects of heme oxygenase-1 in the
failing heart. Circulation 2010, 121:1912e1925
31. Barikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J,
Schramm C, Tiegs G, Sass G: Induction of heme oxygenase 1 prevents
progression of liver ﬁbrosis in Mdr2 knockout mice. Hepatology 2012,
55:553e562
32. Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD,
Choi AM, Morse D: Carbon monoxide suppresses bleomycin-induced
lung ﬁbrosis. Am J Pathol 2005, 166:27e37
33. Ryter SW, Choi AM: Heme oxygenase-1/carbon monoxide: from
metabolism to molecular therapy. Am J Respir Cell Mol Biol 2009, 41:
251e2601247
